Utility of preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios in differential diagnosis of benign, borderline, and malignant ovarian tumors

Yıl 2023, Cilt: 40 Sayı: 2, 333 - 336, 19.07.2023

Sahra Sultan Kara , Esra Keles , Derya Sivri Aydın , Emre Mat , Gazi Yıldız , Rezzan Berna Temoçin , Pınar Birol , Pınar Yıldız

Öz

To investigate the utility of preoperative neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in the differential diagnosis of benign, borderline, and malignant ovarian tumors. This retrospective study was conducted on patients with adnexal masses who underwent surgical resection at Haseki Training and Research Hospital between September 2008 and September 2015. Sociodemographic characteristics, histopathological results and laboratory parameters were obtained from medical reports. Hematological parameters and calculated NLR and PLR were analyzed between tumor groups using IBM SPSS statistics version 22. 381 patients with a mean age of 40.81 (age range: 13-83 years) were included. Of those, 293 patients (76.91%) had benign ovarian tumors, 18 (4.72%) had borderline, and 70 (18.37%) had malignant ovarian tumors. The mean NLR was 2.318 ± 2.29 and the mean PLR was 134.35 ± 59 in benign ovarian tumors, the mean NLR was 4.27±5.23 and the mean PLR was 165.06±98.72 in borderline ovarian tumors, the mean NLR was 4.08±4.37 and the mean PLR was 194.72±114.85 in malign ovarian tumors. The NLR and PLR were significantly higher in malignant than benign or borderline ovarian tumors (all p= 0.0001). The diagnostic cut-off value of NLR for differentiating between benign or borderline and malignant tumors was 1.17, whereas that of PLR for distinguishing between benign/borderline and malignancy was 87.94.The present study indicated that NLR and PLR were significantly higher in ovarian cancers than in benign or borderline ovarian masses. Preoperative NLR and PLR values may help distinguish malignant from benign or borderline ovarian tumors.

Anahtar Kelimeler

ovary tumor, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR)

Kaynakça

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
• 2. Ölmez F, Oğlak SC, Ölmez ÖF, Akbayır Ö, Yılmaz E, Akgöl S, et al. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turk J Obstet Gynecol. 2022;19(3):246-256.
• 3. Akgöl S, Aktürk E, Yıldız Özaydın İ, Ölmez F, Karakaş S, Oğlak SC, et al. Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases. Aegean J Obstet Gynecol. 2021;3(1):19-21.
• 4. Bakacak M, Serin S, Ercan Ö, Köstü B, Bostancı MS, Bakacak Z, et al. Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turk Ger Gynecol Assoc. 2016;17(1):21-25.
• 5. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014; 132: 542-550.
• 6. Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, et al. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016;6:39862.
• 7. Yetmen Dogan O, Eren M. Does pretreatment neutrophıl lymphocyte ratio and platelet-lymphocyte ratıo have a therapeutıc effects in recurrent and/or metastatic gynecological malignancies?. Kocatepe Tıp Dergisi. 2021; 22(2): 125-131.
• 8. Ittiamornlert P, Ruengkhachorn I. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy. BMC Cancer. 2019;19(1):51.
• 9. Abu-Zaid A, Alomar O, Baradwan S, Abuzaid M, Alshahrani MS, Allam HS, et al. Preoperative leukocytosis correlates with unfavorable pathological and survival outcomes in endometrial carcinoma: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;264:88-96.
• 10. Worley MJ Jr, Nitschmann CC, Shoni M, Rauh-Hain JA, Williams KA, Feltmate CM. Preoperative leukocytosis imposes an increased risk of recurrence and death among patients with nonendometrioid endometrial carcinoma. Int J Gynecol Cancer. 2013;23(2):312-317.
• 11. Chen G, Zhu L, Yang Y, Long Y, Li X, Wang Y. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2018;17:1533033818791500.
• 12. Liu M, Feng Y, Zhang Y, Liu H. Evaluation of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio on Predicting Responsiveness to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. Biomed Res Int. 2022;2022:3839670.
• 13. Polat M, Senol T, Ozkaya E, Ogurlu Pakay G, Cikman MS, Konukcu B, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion. Clin Transl Oncol. 2016; 18: 457-463.
• 14. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009; 58:15-23.
• 15. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer. 2015;113(2):311-320.
• 16. Öcal E, Oğlak SC. The Effect of Lymph Node Dissection on Survival in Patients with Advanced Stage (Stage IIIC and IV) Ovarian Cancer. Medical Journal of Mugla Sitki Kocman University. 2020;7(1):40-44.
• 17. Yin X, Wu L, Yang H, Yang H. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(45):e17475.